Trial · NCT04321031
Results by group100
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 100
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) | Placebo | 0.38 | 90% Confidence Interval 0.26 to 0.50 | Proportion of participants | |
Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) | DGAT2i/PF-06865571 25 mg BID | 0.45 | 90% Confidence Interval 0.38 to 0.53 | Proportion of participants | |
Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) | DGAT2i/PF-06865571 75 mg BID | 0.48 | 90% Confidence Interval 0.42 to 0.55 | Proportion of participants | |
Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) | DGAT2i/PF-06865571 150 mg BID | 0.50 | 90% Confidence Interval 0.43 to 0.57 | Proportion of participants | |
Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) | DGAT2i/PF-06865571 300 mg BID | 0.51 | 90% Confidence Interval 0.43 to 0.59 | Proportion of participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | Placebo | 13 | NA to NA | Participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | DGAT2i/PF-06865571 25 mg BID | 16 | 0.61 to 3.05 | Participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | DGAT2i/PF-06865571 75 mg BID | 25 | 0.83 to 3.72 | Participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | DGAT2i/PF-06865571 150 mg BID | 21 | 0.74 to 3.48 | Participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | DGAT2i/PF-06865571 150 mg BID + ACCi/PF-05221304 5 mg BID | 23 | 1.35 to 7.04 | Participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | DGAT2i/PF-06865571 300 mg BID | 14 | 0.58 to 3.08 | Participants | |
Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model | DGAT2i/PF-06865571 300 mg BID + ACCi/PF-05221304 10 mg BID | 19 | 1.19 to 6.56 | Participants | |
| Percent Change From Baseline in Liver Fat at Week 48: Bayesian Dose Response Model | Placebo | -10.79 | 90% Confidence Interval -38.30 to 18.99 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Bayesian Dose Response Model | DGAT2i/PF-06865571 25 mg BID | -36.76 | 90% Confidence Interval -52.57 to -20.15 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Bayesian Dose Response Model | DGAT2i/PF-06865571 75 mg BID | -46.20 | 90% Confidence Interval -59.64 to -32.82 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Bayesian Dose Response Model | DGAT2i/PF-06865571 150 mg BID | -51.33 | 90% Confidence Interval -66.78 to -36.59 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Bayesian Dose Response Model | DGAT2i/PF-06865571 300 mg BID | -55.53 | 90% Confidence Interval -77.23 to -37.64 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Pairwise Comparisons With Analysis of Covariance (ANCOVA) | Placebo | 1.41 | Standard Error 22.11 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Pairwise Comparisons With Analysis of Covariance (ANCOVA) | DGAT2i/PF-06865571 25 mg BID | -41.00 | Standard Error 18.89 | Percent change | |
| Percent Change From Baseline in Liver Fat at Week 48: Pairwise Comparisons With Analysis of Covariance (ANCOVA) | DGAT2i/PF-06865571 75 mg BID | -42.53 | Standard Error 15.66 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04321031/results